Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.020443 | 0 | 0.5 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.0481189 | 1 | 0.5 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.0481189 | 1 | 0.5 |
Echinococcus granulosus | Pyruvate dehydrogenase lipoamide kinase | 0.0481189 | 1 | 0.5 |
Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.0481189 | 1 | 0.5 |
Trypanosoma brucei | developmentally regulated phosphoprotein | 0.0481189 | 1 | 0.5 |
Brugia malayi | kinase, mitochondrial precursor | 0.0481189 | 1 | 0.5 |
Leishmania major | developmentally regulated phosphoprotein-like protein | 0.0481189 | 1 | 0.5 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.0481189 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0481189 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 18 % | In vivo evaluation of the compound for antimalarial activity against P. berghei in percentage when administered orally in mice | ChEMBL. | 10212135 |
Activity (functional) | = 18 % | In vivo evaluation of the compound for antimalarial activity against P. berghei in percentage when administered orally in mice | ChEMBL. | 10212135 |
Activity (functional) | = 100 % | In vivo evaluation of the compound for antimalarial activity against P. berghei in percentage when administered subcutaneously in mice | ChEMBL. | 10212135 |
Activity (functional) | = 100 % | In vivo evaluation of the compound for antimalarial activity against P. berghei in percentage when administered subcutaneously in mice | ChEMBL. | 10212135 |
IC50 (functional) | = 15 nM | In vitro evaluation of the compound for antimalarial activity against P. falciparum using chloroquine resistant K1 strain | ChEMBL. | 10212135 |
IC50 (functional) | = 15 nM | In vitro evaluation of the compound for antimalarial activity against P. falciparum using chloroquine resistant K1 strain | ChEMBL. | 10212135 |
IC50 (functional) | = 16 nM | In vitro evaluation of the compound for antimalarial activity against P. falciparum using drug resistant NF54 strain | ChEMBL. | 10212135 |
IC50 (functional) | = 16 nM | In vitro evaluation of the compound for antimalarial activity against P. falciparum using drug resistant NF54 strain | ChEMBL. | 10212135 |
Survival (functional) | = 24.7 day | In vivo evaluation of the compound for antimalarial activity against P. berghei in terms of survival days when administered subcutaneously in mice | ChEMBL. | 10212135 |
Survival (functional) | = 24.7 day | In vivo evaluation of the compound for antimalarial activity against P. berghei in terms of survival days when administered subcutaneously in mice | ChEMBL. | 10212135 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 10212135 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.